Short- and long-term individual variation in NT-proBNP levels in patients with stable coronary artery disease

Clinica Chimica Acta

Volumn 422, Issue , 2013, Pages 15-20

  Nordenskjöld, Anna M ^a   Ahlström, Håkan ^b   Eggers, Kai M ^b   Fröbert, Ole ^a   Venge, Per ^b   Lindahl, Bertil ^b  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cardiovascular diseases diagnosis; Immunoassay; Individual variation; NT proBNP; Reference change values

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGE DISTRIBUTION; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL EVALUATION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; FEMALE; HUMAN; IMMUNOASSAY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELIABILITY; SEX DIFFERENCE; STABLE CORONARY ARTERY DISEASE;

ADULT; AGED; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 84876716804     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.03.025     Document Type: Article

References (37)

1. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803-869.
2. Maisel A., Mueller C., Adams K., et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008, 10:824-839.
3. Alehagen U., Dahlstrom U., Rehfeld J.F., Goetze J.P. Prognostic assessment of elderly patients with symptoms of heart failure by combining high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide measurements. Clin Chem 2010, 56:1718-1724.
4. Heeschen C., Hamm C.W., Mitrovic V., Lantelme N.H., White H.D. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004, 110:3206-3212.
5. Jernberg T., Stridsberg M., Venge P., Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002, 40:437-445.
6. Kragelund C., Gronning B., Kober L., Hildebrandt P., Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005, 352:666-675.
7. Eggers K.M., Venge P., Lind L. Prognostic usefulness of the change in N-terminal pro B-type natriuretic peptide levels to predict mortality in a single community cohort aged ≥70 years. Am J Cardiol 2013, 111:131-136.
8. Januzzi J.L., Rehman S.U., Mohammed A.A., et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011, 58:1881-1889.
9. Wu A.H., Smith A., Wieczorek S., et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003, 92:628-631.
10. Pagani F.S.F., Panteghini M. Biological variation on serum concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP). Clin Chem 2003, 49(Suppl.):A34.
11. Melzi d'Eril G., Tagnochetti T., Nauti A., et al. Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. Clin Chem 2003, 49:1554-1555.
12. Fradley M.G., Larson M.G., Cheng S., et al. Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study). Am J Cardiol 2011, 108:1341-1345.
13. Wu A.H. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 2006, 152:828-834.
14. Bruins S., Fokkema M.R., Romer J.W., et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004, 50:2052-2058.
15. Schou M., Gustafsson F., Kjaer A., Hildebrandt P.R. Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J 2007, 28:177-182.
16. Schou M., Gustafsson F., Nielsen P.H., Madsen L.H., Kjaer A., Hildebrandt P.R. Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail 2007, 9:68-74.
17. O'Hanlon R., O'Shea P., Ledwidge M., et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 2007, 13:50-55.
18. Cortés R., Rivera M., Salvador A., et al. Variability of NT-proBNP plasma and urine levels in patients with stable heart failure: a 2-year follow-up study. Heart 2007, 93:957-962.
19. Frankenstein L., Remppis A., Frankenstein J., et al. Variability of N-terminal probrain natriuretic peptide in stable chronic heart failure and its relation to changes in clinical variables. Clin Chem 2009, 55:923-929.
20. Rosello-Lleti E., Calabuig J.R., Morillas P., et al. Variability of NT-proBNP and its relationship with inflammatory status in patients with stable essential hypertension: a 2-year follow-up study. PLoS One 2012, 7:e31189.
21. Nordenskjold A.M., Ahlstrom H., Eggers K.M., et al. Short- and long-term individual variation in cardiac troponin in patients with stable coronary artery disease. Clin Chem 2013, 59:401-409.
22. Johnston N., Jernberg T., Lindahl B., et al. Biochemical indicators of cardiac and renal function in a healthy elderly population. Clin Biochem 2004, 37:210-216.
23. Yeo K.T., Wu A.H., Apple F.S., et al. Multicenter evaluation of the roche NT-proBNP assay and comparison to the biosite triage BNP assay. Clin Chim Acta 2003, 338:107-115.
24. Blackburn H., Keys A., Simonson E., Rautaharju P., Punsar S. The electrocardiogram in population studies. A classification system. Circulation 1960, 21:1160-1175.
25. Abrahamsson P., Andersen K., Eriksson P., Dellborg M. Prognostic value of maximum ST-vector magnitude during the first 24h of vectorcardiographic monitoring in patients with unstable angina pectoris. Eur Heart J 1999, 20:1166-1174.
26. Fraser C.G., Harris E.K. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989, 27:409-437.
27. Fokkema M.R., Herrmann Z., Muskiet F.A., Moecks J. Reference change values for brain natriuretic peptides revisited. Clin Chem 2006, 52:1602-1603.
28. Horn P.S., Feng L., Li Y., Pesce A.J. Effect of outliers and nonhealthy individuals on reference interval estimation. Clin Chem 2001, 47:2137-2145.
29. Goetze J.P., Georg B., Jorgensen H.L., Fahrenkrug J. Chamber-dependent circadian expression of cardiac natriuretic peptides. Regul Pept 2010, 160:140-145.
30. Bentzen H., Pedersen R.S., Pedersen H.B., Nyvad O., Pedersen E.B. Abnormal rhythmic oscillations of atrial natriuretic peptide and brain natriuretic peptide in heart failure. Clin Sci (Lond) 2003, 104:303-312.
31. Pedersen E.B., Pedersen H.B., Jensen K.T. Pulsatile secretion of atrial natriuretic peptide and brain natriuretic peptide in healthy humans. Clin Sci (Lond) 1999, 97:201-206.
32. Goetze J.P., Jorgensen H.L., Sennels H.P., Fahrenkrug J. Diurnal plasma concentrations of natriuretic propeptides in healthy young males. Clin Chem 2012, 58:789-792.
33. Ludka O., Spinar J., Pozdisek Z., et al. Is there circadian variation of big endothelin and NT-proBNP in patients with severe congestive heart failure?. Vnitr Lek 2010, 56:488-493.
34. Clerico A., Carlo Zucchelli G., Pilo A., Passino C., Emdin M. Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. Clin Chem Lab Med 2006, 44:366-378.
35. Bordbar S., Bigi M.A., Aslani A., Rahimi E., Ahmadi N. Effect of endurance and strength exercise on release of brain natriuretic peptide. J Cardiovasc Dis Res 2012, 3:22-25.
36. Hijazi Z., Oldgren J., Andersson U., et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation 2012, 125:1605-1616.
37. Damman K., Ng Kam Chuen M.J., MacFadyen R.J., et al. Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol 2011, 57:2233-2241.